Moreover, CRISPR-based gene editing has expanded the horizons of cancer immunotherapy to the immune checkpoint protein PD-1, akin to the modulation of the PD-1/PD-L1 pathway by PD-L1 inhibition in cancer cells. This evidence concerns the gene PDCD1 and cancer.